4baseCare

Precision Oncology solutions powered by #AI and #genomics getting the attention it deserves ! Thank you C4E for covering 4baseCare and our ambitious plans for advancing Precision Oncology, improving the lives of cancer patients globally ! #funding #startup #seriesA #CancerResearch #CancerCare

🎯 #Solid + #Liquid Biopsies = Comprehensive Cancer Care In the complex battle against cancer, a single approach often falls short. That’s why combining solid biopsy and liquid biopsy is a game-changer in oncology diagnostics. 🔵 Solid biopsy digs deep into the tumor’s roots, uncovering its genetic foundation. 🔴 Liquid biopsy captures the spread, offering a snapshot of how cancer evolves and spreads throughout the body. Together, they provide a comprehensive view of cancer’s complexity, paving the way for precise treatment strategies that adapt to each patient’s unique journey. At 4baseCare, we’re proud to champion innovative solutions like #SoLiQ, uniting #solid and #liquid biopsy insights to empower #oncologists and #patients with actionable information. Because when it comes to conquering cancer, #collaboration is key—between techniques, technologies, and most importantly, people. #PrecisionOncology #CancerDiagnostics #LiquidBiopsy #SolidBiopsy #GenomicTesting #OncologyInnovation #TogetherWeBeatCancer #CancerResearch #CancerCare #InfosysInnovationFund #4baseCare #healthtech Merus N.V.

The FDA has granted accelerated approval to #zenocutuzumab-zbco (#Bizengri) for adults with advanced non-small cell lung cancer (#NSCLC) or pancreatic #adenocarcinoma with #NRG1 gene fusions, after progression on prior therapies. This is the first approved therapy targeting #NRG1 gene fusions. 𝐓𝐡𝐞 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐢𝐬 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐭𝐡𝐞 𝐞𝐍𝐑𝐆𝐲 𝐭𝐫𝐢𝐚𝐥, 𝐰𝐡𝐞𝐫𝐞 𝐳𝐞𝐧𝐨𝐜𝐮𝐭𝐮𝐳𝐮𝐦𝐚𝐛 𝐬𝐡𝐨𝐰𝐞𝐝 𝐚 33% 𝐨𝐯𝐞𝐫𝐚𝐥𝐥 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞 𝐫𝐚𝐭𝐞 (𝐎𝐑𝐑) 𝐟𝐨𝐫 𝐍𝐒𝐂𝐋𝐂 𝐚𝐧𝐝 40% 𝐎𝐑𝐑 𝐟𝐨𝐫 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐜 𝐜𝐚𝐧𝐜𝐞𝐫, 𝐰𝐢𝐭𝐡 𝐝𝐮𝐫𝐚𝐛𝐥𝐞 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞𝐬. 𝐖𝐡𝐲 𝐜𝐡𝐨𝐨𝐬𝐞 4𝐛𝐚𝐬𝐞𝐂𝐚𝐫𝐞 𝐢𝐧 𝐥𝐢𝐠𝐡𝐭 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 ? 👉 4𝐛𝐚𝐬𝐞𝐂𝐚𝐫𝐞 𝐌𝐚𝐱𝐢𝐦𝐢𝐳𝐢𝐞𝐬 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 ! 👉 Case in point- For patients with #metastatic cancer, comprehensive #biomarker screening is crucial to identify precision treatment options. Instead of relying on limited cancer-specific panels (e.g., #lung, #colon, or #BRCA panels), choosing a comprehensive #genomic panel within the patient’s budget is highly recommended. 👉 𝐂𝐚𝐧𝐜𝐞𝐫-𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐩𝐚𝐧𝐞𝐥𝐬 𝐭𝐚𝐫𝐠𝐞𝐭 𝐚 𝐥𝐢𝐦𝐢𝐭𝐞𝐝 𝐬𝐞𝐭 𝐨𝐟 𝐠𝐞𝐧𝐞𝐬 𝐰𝐢𝐭𝐡 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐨𝐟 𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐚𝐧𝐝 𝐭𝐢𝐬𝐬𝐮𝐞-𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, 𝐫𝐞𝐬𝐭𝐫𝐢𝐜𝐭𝐞𝐝 𝐩𝐚𝐧𝐞𝐥𝐬 𝐦𝐚𝐲 𝐨𝐯𝐞𝐫𝐥𝐨𝐨𝐤 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬. We shared this perspective with #oncologists, highlighting patients with #NRG1 fusion-positive cancers identified through 𝐓𝐀𝐑𝐆𝐓 𝐈𝐧𝐝𝐢𝐞𝐠𝐞𝐧𝐞 and 𝐓𝐀𝐑𝐆𝐓 𝐀𝐛𝐬𝐨𝐥𝐮𝐭𝐞 tests. While the drug targeting NRG1 fusions was unavailable in their country, oncologists were actively exploring compassionate use options with the drug’s manufacturer with 4baseCare's initiative ! Now that the drug has been approved, we can get in touch with patients who can experience significant improvements in #clinical outcomes and quality of life, emphasizing the transformative potential of comprehensive genomic testing in precision oncology ! #PrecisionOncology #ComprehensiveGenomics #TargetedTherapy #MetastaticCancer #NRG1Fusion #CancerBiomarkers #CancerTreatment #PersonalizedMedicine #OncologyInnovation #GenomicTesting #TissueAgnosticTherapies #PatientCare #CancerAwareness #ClinicalOutcomes #QualityOfLife #TARGTIndiegene #TARGTAbsolute Avishek Roy Hitesh Goswami Vidya H Veldore Divya Udyawar Uchil Dr. Jinumary Aji John

We are thrilled to announce that Infosys has invested INR 8.3 Cr (nearly $1 Mn) in 4baseCare ! This #investment, executed through #Infosys Innovation Fund, will enable us to further our mission of leveraging advanced #genomics and next-generation digital health technologies to develop personalized #cancer #care solutions. 🤝⭐️ We extend our heartfelt #gratitude to Inc42 Media for featuring our story and highlighting our efforts in transforming precision oncology in #Asia and the #MiddleEast ! Your support amplifies our commitment to providing holistic support to patients in their fight against cancer. -https://lnkd.in/dWAKASjG Thank you for being a part of our journey Inc42 Media ! - Hitesh Goswami Kshitij Rishi and team 4baseCare For more information about our solutions and services, please visit our website. - https://4basecare.com/ - 4baseCare HR & Marketing

👉Introducing #SoLiQ – The Best of Both Worlds 🔬 #Solid biopsy targets. 💧 #Liquid biopsy tracks. United, they expose cancer’s ever-changing nature. #Cancer is dynamic, and so is our approach to precision oncology. At 4baseCare, #SoLiQ combines insights from both solid and liquid biopsies to ensure nothing goes unnoticed, empowering #clinicians and #patients with comprehensive genomic insights ( #CGP ). 👉Together, we aim to stay one step ahead of cancer. 🤝 Together We Beat Cancer ! #PrecisionOncology #SoLiQ #LiquidBiopsy #CancerResearch #CancerCare #SolidBiopsy #4baseCare #GenomicsInCancer #Cancer

Congratulations to 4baseCare for securing this significant investment in precision oncology. We are happy to support this important field of targeted therapy and personalised cancer care! Hitesh Goswami Department of Biotechnology Rajesh Gokhale Priyank M Kharge Dinesh Gundu Rao Biotechnology Industry Research Assistance Council (BIRAC) Atal Innovation Mission Official IT BT Department, Karnataka Dr. Ekroop Caur

#BRCA1 & #BRCA2: The “Dynamic DNA Duo,” tirelessly protecting against #breast and #ovarian cancer—until mutations force them to hang up their capes. #MLH1 & #MSH2: The “Mismatch Repair Mechanics,” fixing DNA errors to keep us safe—unless they’re out of order, giving Lynch syndrome a free pass to cause trouble. 🧬 In the intricate world of #genetics, superheroes exist—but even they need check-ups. Genetic testing helps identify mutations early, empowering us to act and protect. 👉Know your heroes. Know your #risks. Every Cancer Has a Story- And We Give It A Voice ! - Divya Udyawar Uchil

#Solid and #Liquid Biopsy: A Powerful Duo in Precision Oncology 👉 Solid biopsies analyze the tumor’s foundation—providing a clear picture of its biology, mutations, and treatment targets. 👉Liquid biopsies detect the ripples—capturing real-time changes in cancer through circulating tumor DNA (#ctDNA) and other biomarkers in blood. ➕When combined, they offer a comprehensive view of cancer:- 1. Solid biopsy identifies the tumor’s core characteristics. 2. Liquid biopsy monitors treatment response, tracks disease progression, and detects resistance early. Together, they address every layer of #cancer—making care more targeted, monitoring proactive, and outcomes more effective ! #PrecisionOncology #4baseCare #TargetedTherapy #CancerResearch #CancerCare #GoSoliQ

Neoadjuvant niraparib plus dostarlimab produced responses for a small cohort of patients with germline BRCA-mutated estrogen receptor–positive/HER2-negative breast cancer. San Antonio Breast Cancer Symposium https://lnkd.in/dE9z6_Xs #SABCS24 #bcsm #cancer #oncology

A True Example of #Compassion and #Dedication in #Oncology~ In a time when access to quality #healthcare remains a challenge for many, Dr. Amol Akhade stands as a beacon of #hope and #humanity. For over 11 years, he has been selflessly serving poor cancer patients in #Mumbai—free of cost ! From providing free first and second-line chemotherapy to facilitating targeted therapies like #trastuzumab and #bevacizumab through government schemes like #AyushmanBharat and #MPAJY, Dr. Akhade’s efforts are making a real difference in the lives of underserved patients. 👉The impact of such initiatives goes beyond treatment—it brings #dignity, relief, and renewed hope to those who need it the most. 🙌 Dr. Akhade’s work is a reminder that every small contribution matters. His dedication to giving back to society, combined with his humility, sets an example for us all. To all the heroes in #healthcare—like Dr. Akhade —your work inspires us every day. Let’s continue to #celebrate and #amplify such stories of #compassion and #purpose. Kudos to Amol Akhade for being a #changemaker in #oncology care!